Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,800.00
Bid: 14,876.00
Ask: 9,919.00
Change: 402.00 (3.24%)
Spread: -4,957.00 (-33.322%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,398.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET PRE-OPEN: Diploma And Victrex Pull Interim Dividends

Mon, 11th May 2020 07:46

(Alliance News) - Stock prices in London are seen opening higher on Monday after the long bank holiday weekend amid tentative steps by the UK government to ease its two-month coronavirus lockdown.

In early company news, industrial firms Diploma and Victrex delivered solid interim results, but both withdrew dividend payments due to uncertainty caused by the health crisis.

IG futures indicate the FTSE 100 index is to open 58.10 points higher at 5,994.10. The blue-chip index closed up 82.22 points, or 1.4% at 5,936.00 on Thursday. The London market was closed on Friday for the VE Day celebrations.

Technical products supplier Diploma said it delivered a robust first-half performance in the face of the Covid-19 pandemic.

For the half-year ended March 31, revenue rose 9% to GBP283.6 million from GBP260.4 million last year, and pretax profit increased 4% to GBP41.6 million from GBP40.1 million.

However, Diploma has decided to suspend payment of an interim dividend.

Looking ahead, Diploma said its outlook for the second half remains uncertain as the global response to Covid-19 pandemic hurts its operations in many of its major markets.

"The group has a resilient and proven business model supported by operating in structurally attractive and diverse sectors and geographies and has a strong balance sheet and liquidity position. The board remains confident in the group's future and expects the group to deliver growth and strong shareholder value creation in the medium term," Diploma said.

Speciality chemicals company Victrex said that, despite global demand for chemicals remaining uncertain, it delivered a solid first half which was in line with expectations.

For the six months to March 31, revenue rose 4% to GBP151.5 million from GBP145.7 million a year before; however, pretax profit edged lower to GBP49.9 million from GBP50.2 million reflecting exceptional items of GBP2.1 million related to the group's China subsidiary investment.

Victrex deferred its interim dividend due to the coronavirus.

It said it made a solid start to the second half with a strong order book.

"We have implemented a range of cash-conservation measures, including deferring our debottlenecking programme and a decision on our interim dividend, and alongside our net cash position and available facilities, our balance sheet remains strong. As previously communicated, with significant macro and end-market uncertainty, we are unable to provide detailed guidance on full-year expectations. We believe the proactive actions we are taking are appropriate to minimise disruption and on a long-term basis, our Polymer & Parts strategy keeps us well placed to deliver our range of medium to long term growth opportunities," Victrex Chief Executive Jakob Sigurdsson said.

AstraZeneca and Daiichi Sankyo Co said that their jointly developed drug Enhertu has been granted breakthrough therapy designation in the US for metastatic gastric cancer.

The pharmaceutical companies said this designation, granted by the US Food & Drug Administration, is designed to accelerate the development and regulatory review of potential new medicines intended to treat a serious condition and address a significant unmet medical need. The FDA's decision was based on data from phase 2 and phase 1 clinical trials, the companies said.

In addition, AstraZeneca said its Lynparza treatment has been approved in the US as first-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer.

UK Prime Minister Boris Johnson on Monday will provide more detailed plans to gradually ease the coronavirus lockdown when the government publishes its official guidance amid widespread calls for clarity.

The prime minister will also face members of Parliament on Monday after offering his "first sketch of a road map" for restarting the economy and social lives in England. He will give a statement to the Commons, with more information expected on a Covid-19 alert system, use of face coverings and the return of professional football.

In a broadcast from Downing Street on Sunday evening, the PM said a phased reopening of schools and non-essential shops in England could potentially begin from June 1 if the transmission can be reduced.

Johnson also said Sunday that Britain would "soon" quarantine air passengers from abroad due to the coronavirus pandemic.

In France, people will from Monday be able to walk outside for the first time in nearly eight weeks without filling in a permit, teachers will start to return to schools, and some shops will reopen. Bars, restaurants, theatres and cinemas will, however, remain closed.

Spaniards outside of urban hotspots such as Madrid and Barcelona - which remain under lockdown - made plans to meet friends and family in bars and restaurants that have outdoor spaces.

The pound was quoted at USD1.2412, up from USD1.2308 at the London equities close on Thursday.

The EU and UK are to take another run at making headway on a post-Brexit trade deal on Monday in a third round of negotiations held by video conference.

The last two rounds yielded little progress, with Brussels lead negotiator Michel Barnier accusing London of refusing to seriously engage with the discussions. Negotiations will continue every day this week until Friday.

The euro was quoted at USD1.0842, up from USD1.0790. Against the yen, the dollar was quoted at JPY106.95, up from JPY106.48.

Brent oil was trading at USD30.60 a barrel Monday morning, lower than USD30.83 late Thursday in London. Gold was quoted at USD1,704.10 an ounce, firm from USD1,700.80.

The Japanese Nikkei 225 index closed up 1.1% on Monday. In China, the Shanghai Composite is down 0.3%, while the Hang Seng index in Hong Kong is up 1.7%.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
20 Jun 2024 10:56

TOP NEWS: AstraZeneca's Truqap gets OK from EU for breast cancer form

(Alliance News) - AstraZeneca PLC on Thursday said that the EU approved its prescription medicine Truqap, in combination with hormonal therapy Faslodex, for the treatment of a form of breast cancer.

Read more
18 Jun 2024 09:33

TOP NEWS: AstraZeneca disappointed by breast cancer drug trial results

(Alliance News) - AstraZeneca PLC on Tuesday said findings from a breast cancer drug trial showed that Truqap did not meet its primary endpoints.

Read more
18 Jun 2024 07:51

LONDON BRIEFING: Ashtead profit declines; Whitbread sales rise

(Alliance News) - London's FTSE 100 is called to open higher on Tuesday, taking confidence from a decent showing for US equities overnight, with inflation data and central bank decisions the key plot points as the week progresses.

Read more
18 Jun 2024 07:17

AstraZeneca trial fails to treat 'challenging' breast cancer

(Sharecast News) - AstraZeneca announced on Tuesday that the phase three 'CAPItello-290' trial for 'Truqap', or capivasertib, in combination with paclitaxel did not achieve its primary endpoints.

Read more
17 Jun 2024 09:09

TOP NEWS: Astra's Imfinzi plus chemo approved for cancer form in US

(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "important new option" for patients.

Read more
17 Jun 2024 07:48

LONDON BRIEFING: Astra gets US drug approval; Ascential trades in line

(Alliance News) - London's FTSE 100 is called to open solidly higher on Monday, recovering some poise after a tricky week, with eyes turning to the Bank of England.

Read more
17 Jun 2024 07:23

IN BRIEF: AstraZeneca gets positive cancer test results for Calquence

AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Reports promising test results for one of its cancer therapies. The Echo phase III trial shows that Calquence, when used in combination with bendamustine and rituximab, demonstrates a clinically meaningful improvement in progression-free survival in patients with untreated mantle cell lymphoma. Compared to standard-of-care chemoimmunotherapy, the combination with Calquence, whose generic name is acalabrutinib, shows a 27% reduced risk of disease progression or death. Mantle cell lymphoma is rare and typically aggressive form of non-Hodgkin lymphoma, Astra explains.

Read more
17 Jun 2024 07:15

AstraZeneca's Imfinzi gets US approval for endometrial cancer patients

(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer.

Read more
12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

Read more
10 Jun 2024 09:10

LONDON BROKER RATINGS: JPMorgan cuts Aviva but lifts M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday:

Read more
10 Jun 2024 08:30

TOP NEWS: Astra's Tagrisso gets US priority review for lung cancer

(Alliance News) - AstraZeneca PLC on Monday celebrated a breakthrough therapy designation for its cancer drug Tagrisso, aimed at treating a form of non-small cell lung cancer.

Read more
10 Jun 2024 07:37

LONDON BRIEFING: FTSE called down amid political uncertainty in EU

(Alliance News) - Stocks in London are called to open lower on Monday, setting off the week on the backfoot, with eyes on the US Federal Reserve's latest interest rate decision.

Read more
10 Jun 2024 06:25

London pre-open: Stocks set for lower start after EU elections

(Sharecast News) - Stocks in London look primed for a lower start as investors digest the gains made by far right parties in Austria, Germany, but above all France, at the European Union elections that were held at the weekend.

Read more
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.